Wednesday, June 24, 2020

University of Iowa Pharmaceuticals (UI Pharmaceuticals), a division of the University of Iowa College of Pharmacy, is actively involved in supporting the fight against COVID-19.

UI Pharmaceuticals, the largest and most experienced university-affiliated FDA-registered pharmaceutical facility in the United States that produces both sterile and non-sterile dosage forms, is supporting Constant Therapeutics, LLC., by manufacturing clinical drug supplies of their investigational drug TXA127. This drug candidate is being evaluated as a possible treatment for the symptoms of COVID-19 infection.

UI Pharmaceuticals has prioritized COVID-19 related projects, and as such, the manufacturing facility was able to release the product for shipment within eight weeks of the active pharmaceutical ingredient (API) arriving at the facility. TXA127 is a pharmaceutical formulation of the natural human peptide, angiotensin-(1-7). TXA127 is designed to restore angiotensin-(1-7) levels, which are reduced in COVID-19 infected patients due to inactivation of angiotensin converting enzyme 2 (ACE2) by virus. This restoration eventually leads to improved pulmonary function, which is one of the normal biologic effects of angiotensin-(1-7).

UI Pharmaceuticals is proud to have been able to support this study by preparing the investigational drug supply and is ready to collaborate with clients trying to accelerate novel treatments into human clinical trials. For more information, visit:  uip.pharmacy.uiowa.edu/about-us/contact-us

For information on Constant Therapeutics, LLC., and their drug development projects go to: 

constanttherapeutics.com/programs/

statnews.com/2020/06/10/coronavirus-lungs-enzyme/